PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | The NEW ENGLAND JOURNAL Of MEDICINE

Authors: Andrea Cercek, M.D., Melissa Lumish, M.D. https://orcid.org/0000-0003-4173-5567, Jenna Sinopoli, N.P., Jill Weiss, B.A., Jinru Shia, M.D., MichelleLamendola-Essel, D.H.Sc., Imane H. El Dika, M.D., and Luis A. Diaz, Jr., M.D.

BACKGROUND

Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. Because mismatch repair–deficient colorectal cancer is responsive to programmed death 1 (PD-1) blockade in the context of metastatic disease, it was hypothesized that checkpoint blockade could be effective in patients with mismatch repair–deficient, locally advanced rectal cancer.

METHODS

We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti–PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair–deficient stage II or III rectal adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy and surgery. Patients who had a clinical complete response after completion of dostarlimab therapy would proceed without chemoradiotherapy and surgery. The primary end points are sustained clinical complete response 12 months after completion of dostarlimab therapy or pathological complete response after completion of dostarlimab therapy with or without chemoradiotherapy and overall response to neoadjuvant dostarlimab therapy with or without chemoradiotherapy.
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

RESULTS

A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose–positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported.

CONCLUSIONS

Mismatch repair–deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response. (Funded by the Simon and Eve Colin Foundation and others; ClinicalTrials.gov number, NCT04165772.)
Locally advanced rectal cancer is typically managed with multimodal therapy, including chemotherapy, radiation, and surgery. Current evidence supports a strategy involving the use of neoadjuvant therapy, in which induction chemotherapy with a fluoropyrimidine in combination with oxaliplatin is followed by chemoradiotherapy and then surgery.1-3 This approach results in a pathological complete response in up to a quarter of patients, but it is associated with marked complications and toxic effects — including bowel, urinary, and sexual dysfunction; infertility; and altered quality of life — in a substantial proportion of patients.4-6 In patients undergoing surgery, resection of the rectum is life-altering and often warrants a permanent diverting colostomy.6,7 Owing to the complications of surgery and the high frequency of pathological complete response, interest in organ-sparing nonoperative management is increasing. The use of clinical complete response that is achieved with neoadjuvant treatment as a surrogate for pathological complete response provides patients with a nonoperative option that results in a survival benefit that is similar to that in patients undergoing surgical resection.8-11
Approximately 5 to 10% of rectal adenocarcinomas are mismatch-repair deficient, and these tumors have been shown to respond poorly to standard chemotherapy regimens, including neoadjuvant chemotherapy in locally advanced rectal cancer.12-14 Immune checkpoint blockade alone has been shown to be highly effective as first-line treatment for patients with mismatch repair–deficient metastatic colorectal cancer, as well as for patients with treatment-refractory disease, with objective response rates of 33 to 55%, clinically significant durability of response, and prolonged overall survival.15-17
On the basis of the benefits seen in the context of metastatic disease, we hypothesized that single-agent programmed death 1 (PD-1) blockade alone might be beneficial in mismatch repair–deficient, locally advanced rectal cancer. To test this hypothesis, we initiated a phase 2 study to investigate the overall response and frequency of sustained clinical complete response to neoadjuvant treatment with dostarlimab, a PD-1 inhibitor, in this patient population.

Skip The Scoop | Seek Understanding

Bannon’s War Room | Morning Edition Hour 1 | Recorded April 15, 2021 | Video: 48 Minutes 50 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded April 15, 2021 | Video: 48 Minutes 47 Seconds

Show Me

Bannon’s War Room | Evening Edition | Recorded April 15, 2021 | Video: 48 Minutes 47 Seconds

Show Me

16 COVID-19 deaths, 1,715 new infections reported in Minnesota

Show Me

Minneapolis Police Arrest at Least 60 After Days of Unrest

Show Me

Former Minnesota cop charged in shooting of Black motorist

Show Me

‘Get The F**k Out Of Here!’: Protesters Pelt CNN Crew With Bottle, Chase Them Away From Brooklyn Center Police District

Show Me

Minnesota protesters, police clash for fourth straight night after Daunte Wright shooting

Show Me

Portland protestors set fires after fatal Minnesota police shooting, continue to besiege city

Show Me

Exclusive: ‘Do Not Use Justice for Blacks as Excuse to Destroy This Nation’—Bob Woodson

Show Me

BLM’s ‘Marxist’ Co-Founder Raked in $20,000 a Month as Chairwoman of Jail Reform Group

Show Me

Russian troops paint their tanks with ‘invasion stripes’: Cold War-era paint markings are spotted as Putin masses 80,000 troops on the Ukranian border in defiance of US president Biden’s call for restraint

Show Me

Democrats planning to unveil bill that would add 4 justices to Supreme Court

Show Me

Big Tech ‘Making Billions’ Off Surveillance Advertising | Children’s Health Defense

Show Me

The Racist Incident That Wasn’t

Show Me

VIDEO: Tucker Slams ADL for Opposing Israeli Demographic Change While Promoting It In America

Show Me

Biden Pulls the Plug on Afghan War at the Risk of Turmoil Ahead

Show Me

CIA shocker: Obama fundraiser says he was U.S. intel asset, alleges spy agency ‘abuses’

Show Me

Florida House Passes Bill to Keep Trans Athletes Out of Girls’ Sports

Show Me

CNN Cheers On More Covid Deaths | Project Veritas Exposé | Video: 2 Minutes 19 Seconds

Show Me

April 14, 2021 | Nightly News Rebroadcast | Video: 47 Minutes 44 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 1 | Recorded April 14, 2021 | Video: 48 Minutes 33 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded April 14, 2021 | Video: 48 Minutes 38 Seconds

Show Me

Bannon’s War Room | Evening Edition | Recorded April 14, 2021 | Video: 49 Minutes

Show Me

Protesters take to the streets of Minneapolis for a third night over Daunte Wright shooting

Show Me

(VIDEO) Police body cam video of shooting in Minnesota

Show Me

China launches hotline for netizens to report ‘illegal’ history comments

Show Me

MLB Boycotted Georgia a Day After Expanding China Deal

Show Me

April 13, 2021 | Nightly News Rebroadcast | Video: 50 Minutes 17 Seconds

Show Me

Justice Thomas shows how we can end Big Tech censorship for good

Show Me

Books by John Steinbeck, Harper Lee, Sherman Alexie among most objected to in 2020

Show Me

The Epoch Times along with NTD, Battling For The Chinese People’s Freedom For Over 20 Years, Demonitized By Youtube and Certain Broadcasts Blocked By Both Vimeo & YouTube Attacked In Hong Kong By Hammer Wielding Arsonists

Show Me

America First Coalition Demands DeSantis Strengthen Florida’s Big Tech Bills To End Online Censorship

Show Me

Chinese Propaganda Group Has Spent Years Cozying up to Black Colleges

Show Me

Mike Pompeo slams China’s ‘Genocide Olympics,’ urges American athletes to boycott it

Show Me

‘Appalling But Not Unexpected’: Pompeo Condemns Attack on Hong Kong Epoch Times Printing Press

Show Me

Commentary: The Importance of the Commission on Unalienable Rights

Show Me

Facebook ‘Supreme Court’ Empowered to Demand More Censorship

Show Me

South African COVID variant can ‘break through’ Pfizer vaccine: study

Show Me

Oopsie Daisy | “CCP Virus Variant Affects Vaccinated People More Than Unvaccinated People: Study”

Show Me